Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 24;26(7):1817.
doi: 10.3390/molecules26071817.

Searching for Potential Markers of Glomerulopathy in Urine by HS-SPME-GC×GC TOFMS

Tomasz Ligor  1   2 , Joanna Zawadzka  3 , Grzegorz Strączyński  4 , Rosa M González Paredes  5 , Anna Wenda-Piesik  6 , Ileana Andreea Ratiu  2   7 , Marek Muszytowski  3
Affiliations
Clinical Trial

Searching for Potential Markers of Glomerulopathy in Urine by HS-SPME-GC×GC TOFMS

Tomasz Ligor et al. Molecules. .

Abstract

Volatile organic compounds (VOCs) exiting in urine are potential biomarkers of chronic kidney diseases. Headspace solid phase microextraction (HS-SPME) was applied for extraction VOCs over the urine samples. Volatile metabolites were separated and identified by means of two-dimensional gas chromatography and time of flight mass spectrometry (GC × GC TOF MS). Patients with glomerular diseases (n = 27) and healthy controls (n = 20) were recruited in the study. Different VOCs profiles were obtained from patients and control. Developed methodology offers the opportunity to examine the metabolic profile associated with glomerulopathy. Four compounds found in elevated amounts in the patients group, i.e., methyl hexadecanoate; 9-hexadecen-1-ol; 6,10-dimethyl-5,9-undecadien-2-one and 2-pentanone were proposed as markers of glomerular diseases.

Keywords: comprehensive two-dimensional gas chromatography; kidney diseases; urine analysis; volatile organic compounds.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Optimization of extraction parameters, including comparison of PDMS/DVB, Carboxen/PDMS and PDMS coatings for extraction of VOC (part (A,A1)), different extraction temperatures (part (B,B1)) and extraction time (part (C,C1)). The boxplots in the upper were drawn according with total peak area of extracted VOCs (subfigures A–C), while the bottom box plots represent the number of extracted VOCs (subfigures A1–C1). Optimization of extraction parameters, including comparison of Polydimethylsiloxane/Divinylbenzene (PDMS/DVB), Carboxen/PDMS (CAR/PDMS), Polydimethylsiloxane (PDMS) for extraction of VOC (part A), different extraction temperatures (part B) and extraction time (part C). The boxplots in the upper were drawn according with total peak area of extracted VOCs (subfigures A–C), while the bottom box plots represent the number of extracted VOCs (subfigures A1–C1).
Figure 2
Figure 2
Network analyses presenting separation between the two investigated groups based on the VOCs specific for patients with glomerular diseases (brown diamonds), VOCs common between groups (yellow diamonds) and VOCs characteristic for healthy group (green diamonds), where H 1 to 20 represents the number of healthy control and P 1 to 27 the number of patients.
Figure 3
Figure 3
Heat map combined with dendrogram presenting hierarchical clusters segregation according with patient and control groups, where H 1to 20 represents the number of healthy control and P 1 to 27 the number of patients.
Figure 4
Figure 4
Principal component analyses (PCA) used to display variation between statistically significant determined VOCs, where: 1. cyclohexanone; 2. 3-ethylcyclopentanone; 3. 3-hexanone; 4. 3-heptanone; 5. methyl hexadecanoate; 6. 9-hexadecen-1-ol; 7. 3-methyl-2-pentanone; 8. 6,10-dimethyl-5,9-undecadien-2-one; 9. 2-pentanone; 10. acetophenone; 11. 2-methoxy-4-vinylphenol; 12. 1-decanol; 13. N-acetylpyrrole; 14. 6-methylhept-5-en-2-one; 15. dimethyl sulfone; 15. dimethyl sulfone; 16. 1-tetradecanol, 17. 4-heptanone; 18. benzaldehyde; 19. 2-nonanone; 20. 5-methyl-3-hexanone; 21. dimethyl trisulfide; 22. 2-aminobenzaldehyde; 23. 3-methylcyclopentanone; 24. hexanal; 25. 1-octanol; 26. benzeneacetaldehyde; 27. 2,5-dimethylpyrazine; 28. nonanal; 29. 9-octadecen-1-ol; 30. indole; 31. theaspirane; 32. benzonitrile; 33. 2-heptanone; 34. 4-methylphenol; 35. phenol; 36. decanal; 37. 1-methyl-4-(1-methylethenyl)-benzene; 38. N-phenylformamide, 39. ethyl acetate; 40. octanal.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shirasu M., Touhara K. The scent of disease: Volatile organic compounds of the human body related to disease and disorder. J. Biochem. 2011;150:257–266. doi: 10.1093/jb/mvr090. - DOI - PubMed
    1. Wagenstaller M., Buettner A. Characterization of odorants in human urine using a combined chemo-analytical and human-sensory approach: A potential diagnostic strategy. Metabolomics. 2013;9:9–20. doi: 10.1007/s11306-012-0425-5. - DOI
    1. Zlatkis A., Brazell R.S., Poole C.F. The role of organic volatile profiles in clinical diagnosis. Clin. Chem. 1981;27/6:789–797. doi: 10.1093/clinchem/27.6.789. - DOI - PubMed
    1. Mills G.A., Walker V., Mughal H. Quantitative determination of trimethylamine in urine by solidphase microextraction and gas chromatography–mass spectrometry. J. Chromatogr. B. 1999;723:281–285. doi: 10.1016/S0378-4347(98)00542-8. - DOI - PubMed
    1. Smith S., Burden H., Persad R., Whittington K., de Lacy Costello B., Ratcliffe N.M., Probert C.S. A comparative study of the analysis of human urine headspace using gas chromatography–mass spectrometry. J. Breath Res. 2008;2:037022. doi: 10.1088/1752-7155/2/3/037022. - DOI - PubMed

Publication types

LinkOut - more resources